In addition, FXR plays a crucial beneficial role in hepatic triglyceride homeostasis, as well as in glucose metabolism and therefore, FXR agonists are also promising for the treatment of non-alcoholic fatty liver disease (NASH), dyslipidemia and type 2 diabetes (T2DM)13, 14, 15, 16. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.